Duquesne Family Office’s Faeth Therapeutics FTH Stock Holding History

Duquesne Family Office’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,000	Closed	-$69K	–	89
2023 Q4	$69K	Hold	5,000	–	–	﹤0.01%	51
2023 Q3	$80K	Hold	5,000	–	–	﹤0.01%	41
2023 Q2	$114K	Hold	5,000	–	–	﹤0.01%	53
2023 Q1	$150K	Hold	5,000	–	–	0.01%	47
2022 Q4	$149K	Hold	5,000	–	–	0.01%	56
2022 Q3	$155K	Hold	5,000	–	–	0.01%	63
2022 Q2	$227K	Hold	5,000	–	–	0.02%	42
2022 Q1	$231K	Hold	5,000	–	–	0.01%	51
2021 Q4	$580K	Hold	5,000	–	–	0.02%	49
2021 Q3	$1.05M	Hold	5,000	–	–	0.03%	48
2021 Q2	$976K	Hold	5,000	–	–	0.02%	52
2021 Q1	$1.45M	Buy	+5,000	New	+$1.67M	0.03%	63

Other funds holding FTH

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Duquesne Family Office's FTH Position: Q1 2024 in Review

Duquesne Family Office sold out of Faeth Therapeutics (FTH) in Q1 2024, closing a stake of 5,000 shares — an estimated $69K sold.

Duquesne Family Office first reported a position in FTH in Q1 2021 and held it in 12 quarters. The position peaked at $1.45M in Q1 2021. 24 funds tracked by Wall St. Rank hold FTH as of Q1 2024.

Duquesne Family Office reported no remaining Faeth Therapeutics position as of Q1 2024 after selling out during the quarter.
Duquesne Family Office sold 5,000 Faeth Therapeutics shares in Q1 2024, an estimated $69K.
Duquesne Family Office first reported a position in Faeth Therapeutics in Q1 2021 and held it in 12 quarters.
Duquesne Family Office's Faeth Therapeutics position peaked at $1.45M in Q1 2021.
24 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2024.

Based on Duquesne Family Office's 13F filing for Q1 2024, filed 15 May 2024.